Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster study of 10-valent pneumococcal conjugate vaccine versus Prevenar with Hiberix in toddlers previously primed in study 10PN-PD-DIT-036
2015-001506-34Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of 10-valent pneumococcal conjugate vaccine, pneumococcal 7-valent conjugate vaccine and haemophilus influenzae type b vaccine in pneumococcal disease and Haemophilus influenzae type b disease (Hib) (2 arms), sponsored by GSK. Primary endpoint: Occurrence of grade 3 adverse events.
02
Drugs
10-valent pneumococcal conjugate vaccinepneumococcal 7-valent conjugate vaccinehaemophilus influenzae type b vaccine
03
Conditions
pneumococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2015-001506-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001506-34.